Sanofi
Beyfortus Approved to Prevent RSV in Infants & Children
The FDA approved Beyfortus (for the prevention of RSV lower respiratory tract disease in newborns and infants born ...
JULY 18, 2023
Altuviiio Highly Effective Against Bleeding in Children With Severe Hemophilia A
The phase 3 XTEND-Kids study evaluating antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, ...
JUNE 26, 2023
Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients
The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.
FEBRUARY 12, 2019
FDA Approves Cablivi, First Therapy to Treat aTTP
In the United States, acquired thrombotic thrombocytopenic purpura affects fewer than 2,000 adults each year.
FEBRUARY 7, 2019
FDA Advisory Committee Split Over Approval for Zynquista
Committee's concerns centered on whether overall benefits of Zynquista outweighed the risk for patients developing ...
JANUARY 22, 2019
FDA Approves New Indication for Dupixent for Asthma
Dupilumab inhibits the overactive signaling of IL-4 and IL-13, two key proteins that contribute to the Type 2 ...
OCTOBER 20, 2018
FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018
Cigna Signs Value-Based Deal To Cover PCSK9s
Cigna has signed value-based contracts for PCSK9 inhibitors, based on patient response.
JUNE 6, 2016
Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs
Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.
MARCH 24, 2016
